These results suggested that nAChR upregulation could be a self-defense mechanism for some SCLC cells to counteract the anticancer activity of platinum-based chemotherapies through the modulation of cellular redox processes that may deactivate chemotherapies. The gene discussed is CHRNA4; the disease is small cell lung carcinoma.